G1 Therapeutics’ COSELA recommended in updated SCLC guidelines

G1 Therapeutics announced that COSELA has been recommended as a myeloid supportive agent in the updated American Society of Clinical Oncology small cell lung cancer guidelines for patients with untreated or previously treated extensive-stage small cell lung cancer, SCLC, who are undergoing treatment with chemotherapy or chemoimmunotherapy. COSELA is indicated to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for ES-SCLC. “The inclusion of COSELA in these new ASCO SCLC guidelines is essential, as they inform treatment decisions by U.S. physicians caring for people living with small cell lung cancer,” said Raj Malik, M.D., Chief Medical Officer of G1 Therapeutics. “The mounting body of evidence from our clinical trials and real-world studies demonstrates the potential of COSELA to protect the bone marrow of patients with ES-SCLC against the harmful effects of chemotherapy. These updated guidelines provide further clarity and confidence to physicians considering cytotoxic therapies for their patients with untreated and previously treated SCLC.”